Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Radius Expands Abaloparatide License with Theramex to New Territories
Details : Under the licensing agreement, Radius granted Theramex the exclusive commercialization rights to Eladynos (abaloparatide), indicated for the treatment of osteoporosis in postmenopausal
Product Name : Eladynos
Product Type : Peptide
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : DRI Healthcare Trust
Deal Size : $140.0 million
Deal Type : Agreement
Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : $130.0 million
August 14, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : DRI Healthcare Trust
Deal Size : $140.0 million
Deal Type : Agreement
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : Undisclosed
March 20, 2023
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : Undisclosed
Deal Type : Acquisition
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : Undisclosed
August 15, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : $547.0 million
August 15, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Lead Product(s) : Cannabidiol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
Details : Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes.
Product Name : RAD011
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : $547.0 million
June 23, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Gurnet Point Capital
Deal Size : $890.0 million
Deal Type : Acquisition
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Menarini
Deal Size : Inapplicable
Deal Type : Inapplicable
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Details : RAD1901 (elacestrant) is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men.
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Menarini
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Radius Health Update on Abaloparatide Transdermal System
Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.
Product Name : Tymlos
Product Type : Peptide
Upfront Cash : Inapplicable
August 12, 2021
Lead Product(s) : Abaloparatide Acetate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable